People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Biotechnology, Other Travel
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Better Therapeutics, Inc. | — | Biotechnology | Series A | $8.9M | $1.7M | 2023 |
| Volato Group, Inc. | — | Other Travel | Series A | $4.5M | $12.9M | 2024 |
Mark Heinen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Heinen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Perry | 1 | 11 |
| Geoffrey Parker | 1 | 3 |
| Nicholas Cooper | 1 | 3 |
| Matthew Liotta | 1 | 3 |
| Elder Granger | 1 | 3 |
| Richard Carmona | 1 | 3 |
| Michael Nichols | 1 | 2 |
| Andrew Armanino | 1 | 1 |
| Mark Berman | 1 | 1 |
| Risa Lavizzo-Mourey | 1 | 1 |
| Kristin Wynholds | 1 | 1 |
| Frank Karbe | 1 | 1 |
| Michael Prachar | 1 | 1 |
| Christopher Burger | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.